Clinical Trials Directory

Trials / Completed

CompletedNCT04776837

Predicting Disease Progression and/or Recurrence in Cancer

Tumor Markers, Liquid Biopsies, and Patient Reported Outcomes in Metastatic Colorectal, Pancreas, Biliary, and Esophagogastric Cancers

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.

Detailed description

This research study is evaluating how patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival) in patient populations with colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy Massachusetts General Hospital Cancer Center * Patient reported outcomes will be collected through a series of self-administered questionnaires and blood draws will be used to obtain bio and tumor marker information. * Information will also be collected from the participants electronic medical record. * Tissue may be obtained for next-generation sequencing. * The study will conclude after participants are no longer receiving anti-cancer therapies. * It is expected that about 200 people will take part in this research study

Conditions

Interventions

TypeNameDescription
BEHAVIORALObservational CohortPatients will be followed by collecting clinical data, biospecimens, and quality of life assessment

Timeline

Start date
2019-05-15
Primary completion
2021-11-19
Completion
2021-11-19
First posted
2021-03-02
Last updated
2022-08-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04776837. Inclusion in this directory is not an endorsement.